Skip Navigation

skip navigationNIDDK Home
NIDDK Reference Collection
Diet   Exercise   Health  
Home Page
-  

FAQ

Detailed Search

- -
NIDDK INFORMATION SERVICES
- -

Diabetes

Digestive Diseases

Endocrine and Metabolic Diseases

Hematologic Diseases

Kidney and Urologic Diseases

Weight-control Information Network

-
NIDDK EDUCATION
PROGRAMS

- -

National Diabetes Education Program

National Kidney Disease Education Program

-
- - -
NIDDK Home
-
Contact Us
-
New Search
-
Topic: kidney and urologic diseases (ku)
Title: Medical Therapy for Benign Prostatic Hyperplasia.
Author: Bott, S.R.J.; Foley, C.L.; Kirby, R.S.
Source: IN: Eardley, I., et al, eds. Drug Treatment in Urology. Williston, VT: Blackwell Publishing Inc. 2006. pp. 21-38.
Availability: Available from Blackwell Publishing Inc. P.O.Box 20, Williston, VT 05495. Phone: 1-800-216-2522. Email: orders@aidcvt.com. Website: http://www .blackwellpublishing.com. Price: $99.95.
Abstract: This chapter on medical therapy for benign prostatic hyperplasia (BPH) is from a book that offers a comprehensive summary of the role of pharmacology in urology. The authors note that medical therapy is now widely used as first-line treatment, except in cases of complicated bladder outflow obstruction (BOO) where surgery is more usually performed, or in very mild cases where watchful waiting is the norm. The authors briefly review the epidemiology and natural history of BPH, then discuss alpha-adrenergic antagonists, 5-alpha reductase inhibitors (5ARIs), combination therapy, and phytotherapy-including saw palmetto. The authors conclude that while alpha-blockers have an almost immediate beneficial effect on symptoms and flow, they have no significant impact on the risk of disease progression. By contrast, 5ARIs, when used in men with larger prostates, are capable of both arresting disease progression and reducing the incidence of acute urinary retention (AUR) or the need for BPH-related surgery. The use of both an alpha-blocker and a 5ARI in combination seems appropriate in older men with larger glands and an elevated prostate specific antigen (PSA) score. 4 figures. 3 tables. 46 references.

Format: Book Chapter
Language: English.
Major Keywords: Urologic Diseases. Benign Prostatic Hyperplasia. Drug Therapy. Drug Effects. Pharmacology. Patient Care Management.
Minor Keywords: Patient Selection. Administration and Dosage. Age Factors. Complications. Alternative Medicine. Symptoms.
Publication Number: KUBK11564.
Printer-Friendly Version | Return to Search Results
<-- previous record | next record -->

View NIDDK Publications | NIDDK Health Information | Contact Us

The NIDDK Reference Collection is a service of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.
NIDDK Clearinghouses Publications Catalog
5 Information Way
Bethesda, MD 20892–3568
Phone: 1–800–860–8747
TTY: 1–866–569–1162
Fax: 703–738–4929
Email: catalog@niddk.nih.gov

Privacy | Disclaimers | Accessibility | Public Use of Materials
H H S logo - link to U. S. Department of Health and Human Services NIH logo - link to the National Institute of Health NIDDK logo - link to the National Institute of Diabetes and Digestive and Kidney Diseases